Prof. Charles Craddock of the Queen Elizabeth Hospital in Birmingham, UK, describes how doctors check if an acute myeloid leukaemia (AML) patient is responding to treatment. Following a round of intensive chemotherapy, a bone marrow sample is collected and tested. This helps determine if a patients has gone into remission.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL.

This programme has been supported by Pfizer, through an unrestricted educational grant to the Patient Empowerment Foundation.

свернуть